Board Unveils New Foresight and Signals Products: Revolutionizing Business Planning with AI and Economic Intelligence
19.2.2025 15:00:00 CET | Business Wire | Press release
Board, the leading Enterprise Planning Platform, is transforming the way businesses anticipate and adapt to economic shifts with today’s announcement of Board Foresight and Board Signals. These cutting-edge solutions, developed as a result of Board’s recent acquisition of Prevedere, empower enterprises with real-time economic indicators, predictive analytics, and the expertise of Board’s in-house economists—all backed by exclusive access to over 5 million global datasets.
This release marks a huge step forward in completing Board’s product vision. By harnessing the power of macroeconomic intelligence, the Board Enterprise Planning Platform now enables more comprehensive, collaborative, and continuous planning capabilities than ever before. Board Foresight and Signals give business leaders the ability to look beyond internal historical data, forecast with greater accuracy, scenario plan with more agility, and make strategic decisions with confidence in an increasingly volatile world.
Board Foresight: Continuous planning with external data, AI, and predictive analytics
Board Foresight takes business forecasting to the next level by unlocking the power of external data with expert-curated economic indicators, an advanced correlation engine, and predictive analytics. With real-time updates from millions of external sources, Board Foresight enables enterprises to anticipate market shifts, align business strategies and drive continuous planning.
Key benefits of Board Foresight:
- Expert-Curated Indicators: Get a list of the external factors most likely to impact your industry.
- Powerful Correlation Engine: Connect to your own internal time series data and Foresight will run millions of models to identify your most relevant performance drivers.
- Results Explained by AI: Get a complete understanding of the external factors impacting your business, with clear explanation and interpretation delivered through generative AI.
- Predictive Forecasting to Support Continuous Planning: Forecast with better accuracy and turn continuous planning into a competitive advantage.
Learn more at https://www.board.com/en/product/foresight.
Board Signals: Make smarter strategic decisions with expert-curated external data
Board Signals provides decision-makers with real-time, industry-specific economic indicators to help them navigate market volatility with confidence. Designed for strategic planners, executive officers, and board members, Board Signals delivers clear, actionable intelligence to drive smarter business decisions and is available today.
Key benefits of Board Signals:
- Industry-Specific Economic Intelligence: Get expert-curated indicators tailored to your industry, monitored and updated regularly by Board’s in-house economists.
- Smart Alerts on Market Volatility: Receive real-time alerts on headwinds and tailwinds impacting your business so you can respond in an agile manner to capitalize on opportunities and mitigate risks.
- Indicator Reports and Industry Outlook Score: Visualize economic conditions with intuitive reports and scoring to support strategic decision-making.
Learn more at https://www.board.com/en/product/signals.
An Innovative Breakthrough in Enterprise Planning
David Marmer, SVP of Product at Board, emphasized the significance of these new solutions:
“The introduction of Board Foresight and Board Signals marks a new beginning for enterprise planning. For too long, businesses have relied solely on historical internal data, missing the critical external factors that drive success or failure. With the power of over 5 million datasets, AI-driven analytics, and expert economic intelligence, our customers can now plan continuously for the future with greater confidence and precision. These innovations reflect Board’s commitment to giving our customers the tools they need to stay ahead.”
Visionary Brands are Leading the Way
Leading enterprises are already leveraging Board Signals and Board Foresight to enhance their decision-making. Milwaukee Tool, Whataburger, and Kraft Heinz are among the early adopters benefiting from these solutions, using them to navigate economic volatility, optimize inventory, and drive strategic growth.
“This has been a game-changer for Whataburger,” says Pete Valadez, Senior Director of Financial Planning & Analysis at Whataburger. “By incorporating external data and predictive analytics into our forecasting process, we’ve been able to dramatically improve our accuracy and avoid missed expectations. The real-time alerts and collaborative nature of the solution have empowered our entire team to make data-driven decisions with confidence.”
General Availability
Board Signals and Board Foresight are available now globally.
About Board
The Board Enterprise Planning Platform powers financial and operational planning for more than 2,000 organizations worldwide. Industry leaders trust Board to turn complex data into better decisions with AI, analytics, and tailor-made solutions for enterprise-grade challenges. Global brands including H&M, BASF, Burberry, Toyota, Coca-Cola, KPMG, and HSBC use Board to enhance workflows and strengthen their competitive edge. Founded in 1994, and now with 25 offices worldwide, Board is recognized by leading analysts including Gartner, IDC, and BARC.
For more information, visit www.board.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250219004034/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom